A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

• Drug: PF-04171327 10 mg
  
  PF-04171327 10 mg tablet every day for 14 days
• Other: Prednisone Placebo
  
  Placebo for Prednisone 5 mg tablet every day for 14 days
• Drug: PF-04171327 25 mg
  
  PF-04171327 25 mg tablet every day for 14 days
• Drug: Prednisone 5 mg
  
  Prednisone 5 mg tablet every day for 14 days
• Other: Placebo for PF-04171327
  
  Placebo for PF-04171327 every day for 14 days
• Other: Placebo
  
  Placebo tablet every day for 14 days
• Other: Placebo for PF-04171327
  
  Placebo tablet every day for 14 days

• Experimental: PF-04171327 10 mg
  
  Interventions:
  

  • Drug: PF-04171327 10 mg
  • Other: Prednisone Placebo
• Experimental: PF-04171327 25 mg
  
  Interventions:
  

  • Drug: PF-04171327 25 mg
  • Other: Prednisone Placebo
• Active Comparator: Prednisone
  
  Interventions:
  

  • Drug: Prednisone 5 mg
  • Other: Placebo for PF-04171327
• Placebo Comparator: Placebo
  
  Interventions:
  

  • Other: Placebo
  • Other: Placebo for PF-04171327

Inclusion Criteria:

• Patients ? 18 years of age, diagnosed with rheumatoid arthritis for a minimum duration of 3 months
• On stable dose of methotrexate for at least 6 weeks prior to screening
• Patient must have minimum disease activity level of ? 6 tender/painful joints, ? 6 swollen joints and CRP ? 0.7 mg/dL
• Not currently receiving steroid medication

Exclusion Criteria:

• Pregnant or nursing women
• Patients that have active infections, TB, HIV and/or Hepatitis B or C
• Patients that have a history of intolerance or significant adverse effects with the use of glucocorticoids